| |MARCH 20268ZYDUS & TORRENT PARTNER TO CO-MARKET SEMAGLUTIDE INJECTIONZydus Lifesciences Limited and Torrent Pharmaceuticals Limited today announced a licensing and supply agreement to co?market semaglutide injection in India.Under the pact, Zydus will manufacture and supply the drug while Torrent Pharma will use its strong chronic therapy presence to market the product under the brand Sembolic.Zydus will continue to market the semaglutide injection in India under its brands Semaglyn, Mashema, and Alterme. Torrent Pharma's semi?exclusive rights allow it to promote and sell the product nationwide under its own brand. As part of the deal, Torrent Pharma will pay an upfront licensing fee to Zydus.Zydus has developed an innovative semaglutide injection (15 mg/3 ml) in a prefilled cartridge that works with a reusable, patient?friendly pen device. This unique delivery system enables all dose strengths for both diabetes and weight management through one single device, improving convenience, adherence, and long?term compliance--key goals in chronic disease care.Semaglutide is indicated for adults with type 2 diabetes mellitus who need better blood sugar control alongside diet and exercise, including those for whom metformin is unsuitable. The drug is also approved for chronic weight management in adults with obesity (BMI 30 kg/m²) or overweight (BMI 27 kg/m²) with related conditions like hypertension or dyslipidemia. The Indian semaglutide injection market is rapidly evolving as more patients seek advanced GLP?1 therapies.This collaboration brings together Zydus's development and manufacturing strength with Torrent Pharma's field reach, with a shared aim to improve patient access to modern therapies for metabolic disorders. POTOP STORIESPFIZER'S ATIRMOCICLIB BREAST CANCER STUDY SHOWS STRONG RESULTSPfizer Inc. today reported positive topline findings from its Phase 2 FOURLIGHT-1 trial, marking a key milestone in the atirmociclib breast cancer study for patients with HR-positive HER2-negative metastatic breast cancer.The study tested atirmociclib in combination with fulvestrant against fulvestrant alone or everolimus plus exemestane in patients previously treated with CDK4/6 inhibitors.The trial achieved its primary endpoint, showing a statistically significant improvement in progression-free survival in breast cancer, with a hazard ratio of 0.60 and strong p-value significance. Results were consistent across all subgroups, including patients with different prior treatment durations, menopausal status, and presence of visceral disease. Notably, over 90 percent of patients started treatment within three months of prior CDK4/6 therapy, reflecting a real-world setting."These results are especially encouraging given that the FOURLIGHT-1 study enrolled patients whose disease had progressed soon after prior CDK4/6 inhibitor therapy, a difficult-to-treat population," said Jeff Legos, chief oncology officer, Pfizer.He added, "The strength of these data reinforces our confidence that atirmociclib may meaningfully differentiate from the CDK4/6 inhibitor class, the standard-of-care backbone in HR-positive breast cancer, with the potential for improved efficacy and tolerability. We are continuing to accelerate development of this next-generation cell cycle inhibitor in earlier lines of therapy where it may offer even greater benefit for patients."The atirmociclib breast cancer study also showed a manageable safety profile, with only 6.4 percent discontinuation due to adverse events and no new safety concerns. Overall survival data remains immature, with about 20 percent of events reported.Pfizer is advancing a Phase 3 trial and exploring earlier treatment use, aiming to strengthen outcomes in advanced breast cancer treatment and expand options for patients with limited therapies. PO
< Page 7 | Page 9 >